Company Overview

Development Stage

About the Company

[Summary] Making drugs and treatments accessible to all

WuXi AppTec (stock code: 603259.SH/2359.HK) is a leading open-access capability and technology platform company. It provides comprehensive, integrated laboratory research and manufacturing services from drug discovery, development to commercialization for the global pharmaceutical and medical device industries. Guided by the principles of research-first and customer-centricity, WuXi AppTec helps global clients shorten drug and medical device development cycles and reduce R&D costs through its high-cost-performance and efficient service platform. The WuXi AppTec platform encompasses chemical drug R&D and manufacturing, cell and gene therapy R&D and manufacturing, drug R&D, and medical device testing. It is currently carrying thousands of R&D innovation projects for more than 3,500 innovative partners from over 30 countries worldwide, committed to bringing the latest and best medical and health products to patients globally, realizing the dream of 'making drugs and treatments accessible to all.'

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

How Fast Is Hiring Growing? (20 open positions)

Manage
Note: How fast is hiring at WuXi AppTec (Wuhan) New Drug Development Co., Ltd. growing? 2026: 77 openings (up 235%), 2025: 23 openings (down 12%), 2024: 26 openings (down 73%), 2023: 97 openings (up 29%), 2022: 75 openings (up 23%), 2021: 61 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Flat 0%-
  • 2024: Down 47%
  • 2023: Down 42%
  • 2022: Up 550%
Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at WuXi AppTec (Wuhan) New Drug Development Co., Ltd. growing? Master's recruitment over the years: 2025: 8 openings (flat), 2024: 8 openings (down 47%), 2023: 15 openings (down 42%), 2022: 26 openings (up 550%), 2021: 4 openings.

Doctoral Degree Job Demand Analysis

(More)
+467%
Growth Rate
2026 vs 2025
  • 2025: Down 50%
  • 2024: Down 85%
  • 2023: Up 33%
  • 2022: Up 2900%
Doctoral Hiring by Year: 2026 — 14 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at WuXi AppTec (Wuhan) New Drug Development Co., Ltd. growing? Doctorate recruitment over the years: 2026: 17 openings (up 467%), 2025: 3 openings (down 50%), 2024: 6 openings (down 85%), 2023: 40 openings (up 33%), 2022: 30 openings (up 2900%), 2021: 1 openings.

R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at WuXi AppTec (Wuhan) New Drug Development Co., Ltd.? Based on an analysis of 's job postings over the past year, "其他(研发和技术类)" demand: 80.6%, "生物/制药/化工/环保类": 79.2%, "科研类": 76.4%, "机械/仪器仪表类": 4.2%, "医疗卫生/美容保健类": 1.4%, "计算机/网络/技术类": 1.4%. For reference only.

— What Are the Salaries Like? (72 records)

Manage
salary range: 2K - 50K, 80.5% of roles pay ¥8-30K
Note: salary statistics are based on 72 salary records from the past year and depend on the job sample. For reference only.
How is the salary at WuXi AppTec (Wuhan) New Drug Development Co., Ltd.?80.5% of positions earn 8-30K, Fresh graduate salary: ¥12.8K。其他(研发和技术类) average salary ¥14.4K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of

(More)
Are salaries high at WuXi AppTec (Wuhan) New Drug Development Co., Ltd.? We provide: 研究员,有机合成,化学,机工,韩语,出口专员,cs,分析,管理工程师,运营,hr,ie,ma,net开发,pr,人力,合规,实习生,物流专,管理专员. Click to view detailed salary analysis by job.

honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Related Industry Tags

Job Category

  • 其他(研发和技术类)
    79.6% of total 79.6%
  • 生物/制药/化工/环保类
    77.4% of total 77.4%
  • 科研类
    76.3% of total 76.3%
  • 教育/培训类
    8.6% of total 8.6%

Education

  • 本科
    60.2% of total 60.2%
  • 硕士
    19.4% of total 19.4%
  • 博士
    19.4% of total 19.4%
  • 大专
    1.1% of total 1.1%

Experience

  • 不限
    59.1% of total 59.1%
  • 1-3年
    26.9% of total 26.9%
  • 应届生
    6.5% of total 6.5%
  • 3-5年
    5.4% of total 5.4%
View Detailed Analysis

What does WuXi AppTec (Wuhan) New Drug Development Co., Ltd. require? Who is WuXi AppTec (Wuhan) New Drug Development Co., Ltd. hiring? recruitment: 其他(研发和技术类)占比最多占79.6%,其次是生物/制药/化工/环保类占77.4%. What education can get in at ? 本科占比最多占60.2%,其次是硕士占19.4%. High education required at ? 硕士占19.4%,博士占19.4%. Work experience required at ? 不限占比最多占59.1%,其次是1-3年占26.9%. Where are the job locations at ? 武汉占比最多占100%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 19,623.896万(元)
Legal Representative: 张朝晖
Date Established:
Credit Code: 91420100562339081Q
Registered Address: 湖北省武汉市东湖新技术开发区豹澥街道九龙中路68号

Partners & Suppliers

入驻光谷生物医药加速器二期 Source
供应商 科技园区开发运营
人福医药委托武汉药明康德进行药物研发服务,包括合成化学与分析。 Source
合作客户 创新药企
武汉药明康德与华中科技大学同济医学院开展药物研发合作,提供实习基地。 Source
供应商 高校/研究院
武汉药明康德与武汉大学联合建立创新药物研发实验室,进行人才合作与技术交流。 Source
供应商 高校/研究院

People who follow this company also follow

Competitors (Similar Companies)

“Making drugs and cures accessible to all”
“A leading open-access capability and technology platform company for p”
医药 维生素B1 维生素 抗生素
“Leading enterprise in Hubei pharmaceutical industry, one of China's to”
“Providing solutions for personalized treatment and health management”
“A technology-driven international pharmaceutical enterprise”
“Trustworthy biological experiment service provider”
新药研发 医药工业 麻醉药 试剂
“Mainly engaged in the research, development and production of active p”
“A large private modern pharmaceutical distribution enterprise in China”
生物科技/生物工程 创新药 药物研发 基因治疗
“Accelerating global biologic drug R&D processes, reducing R&D costs, a”
CRO 新药研发 CDMO 医药
“Research, development, and production of anti-tumor and surgical medic”
“Top 30 enterprise in China's pharmaceutical industry”

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates